Diabetes is a common endocrine disorder, primarily characterised by elevated plasma glucose levels. The disease affects all age groups worldwide. Most patients suffer from Type 2 diabetes, which is mainly due to insulin resistance. It is thought that changes in insulin signalling pathways underlie the development of insulin resistance. This article aims to review recent studies that have elucidated the role of individual proteins in these insulin signalling pathways. These studies have been undertaken using two strategies, one employing mice carrying a global null mutation of particular gene-encoding proteins by the homologous recombination method and another strategy using mice with tissue-specific insulin receptor and/or GLUT4 knockout by the Cre-loxP system. The various phenotypes of these knockout mice, and the light they shed on the etiology of insulin resistance, are discussed. By advancing our understanding of the complex molecular mechanisms underlying insulin resistance, these knock-out models may help us to develop more effective treatments for Type 2 diabetes.
WildS., RoglicG., GreenA., SicreeR., and KingH. (2004) Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. Diabetes Care, 27(5), 1047–1053.
2.
BodenG., ChenX., RuizJ., WhiteJ. V., and RossettiL. (1994) Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest., 93(6), 2438–2446.
3.
BergmanR. N., and AderM. (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol. Metab., 11(9), 351–6.
4.
MlinarB., MarcJ., JanezA., and PfeiferM. (2007) Molecular mechanisms of insulin resistance and associated diseases. Clin. Chim. Acta, 375(1-2), 20–35.
5.
BodenG., and ChenX. (1999) Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes, 48(3), 577–583.
6.
WebberJ. (2003) Energy balance in obesity. Proc. Nutr. Soc., 62(2), 539–543.
7.
KershawE. E., and FlierJ. S. (2004) Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab., 89(6), 2548–2556.
8.
SaltielA. R., and KahnC. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799–806.
9.
LamotheB., BaudryA., DesboisP. (1998) Genetic engineering in mice, impact on insulin signalling and action. Biochem. J., 335(Pt 2), 193–204.
10.
KahnC. R. (2003) Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Exp. Diabesity Res., 4(3), 169–182.
11.
MyersM. G.Jr., and WhiteM. F. (1996) Insulin signal transduction and the IRS proteins. Annu. Rev. Pharmacol. Toxicol., 36, 615–58.
12.
JoostH. G., and ThorensB. (2001) The extended GLUT-family of sugar/polyol transport facilitators, nomenclature, sequence characteristics, and potential function of its novel members (review). Mol. Membr. Biol., 18(4), 247–256.
13.
LouviA., AcciliD., and EfstratiadisA. (1997) Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol., 189(1), 33–48.
14.
JoshiR. L., LamotheB., CordonnierN. (1996) Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. Embo. J., 15(7), 1542–1547.
15.
AcciliD., DragoJ., LeeE. J. (1996) Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat. Genet., 12(1), 106–109.
16.
VirkamakiA., UekiK., and KahnC. R. (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest., 103(7), 931–943.
17.
TamemotoH., KadowakiT., TobeK. (1994) Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature, 372(6502), 182–186.
18.
ArakiE., LipesM. A., PartiM. E. (1994) Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature, 372(6502), 186–190.
19.
KulkarniR. N., WinnayJ. N., DanielsM. (1999) Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J. Clin. Invest., 104(12), R69–75.
20.
AspinwallC. A., LakeyJ. R., and KennedyR. T. (1999) Insulin-stimulated insulin secretion in single pancreatic beta cells. J. Biol. Chem., 274(10), 6360–6365.
21.
AbeH., YamadaN., KamataK. (1998) Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J. Clin. Invest., 101(8), 1784–1788.
22.
WithersD. J., GutierrezJ. S., ToweryH. (1998) Disruption of IRS-2 causes type 2 diabetes in mice. Nature, 391(6670), 900–4.
23.
KubotaN., TobeK., TerauchiY. (2000) Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes, 49(11), 1880–1889.
24.
Mauvais-JarvisF., KulkarniR. N., and KahnC. R. (2002) Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clin. Endocrinol. (Oxf.), 57(1), 1–9.
25.
FantinV. R., WangQ., LienhardG. E., and KellerS. R. (2000) Mice lacking insulin receptor substrate 4 exhibit mild defects in growth, reproduction, and glucose homeostasis. Am. J. Physiol. Endocrinol. Metab., 278(1), E127–133.
26.
ElcheblyM., PayetteP., MichaliszynE. (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science, 283(5407), 1544–1548.
27.
KlamanL. D., BossO., PeroniO. D. (2000) Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase IB-deficient mice. Mol. Cell. Biol., 20(15), 5479–5489.
28.
Mauvais-JarvisF., and KahnC. R. (2000) Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus, what can we learn from transgenic and knockout mice?Diabetes Metab., 26(6), 433–448.
29.
TerauchiY., TsujiY., SatohS. (1999) Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet., 21(2), 230–235.
30.
KatzE. B., StenbitA. E., HattonK., DePinhoR., and CharronM. J. (1995) Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature, 377(6545), 151–155.
31.
BruningJ. C., WinnayJ., CheathamB., and KahnC. R. (1997) Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol. Cell. Biol., 17(3), 1513–1521.
32.
KidoY., BurksD. J., WithersD. (2000) Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J. Clin. Invest., 105(2), 199–205.
33.
Mauvais-JarvisF., UekiK., FrumanD. A. (2002) Reduced expression of the murine p85alpha subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. J. Clin. Invest., 109(1), 141–149.
34.
LaustsenP. G., MichaelM. D., CruteB. E. (2002) Lipoatrophic diabetes in Irs1(–/–)/Irs3(–/–) double knockout mice. Genes Dev, 16(24), 3213–3222.
35.
CurtisS. E. M. M., CruteB. E., KellerS. R., and LienhardG. E. (2000) Double knockout of IRS proteins reveals critical roles of IRS-1 and IRS-3 in the maintenance of glucose homeostasis (abstract). Keystone Symposia, A5.
36.
KahnC. R. (1994) Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes, 43(8), 1066–1084.
37.
BruningJ. C., MichaelM. D., WinnayJ. N. (1998) A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell., 2(5), 559–569.
38.
LauroD., KidoY., CastleA. L. (1998) Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nat. Genet., 20(3), 294–298.
39.
Mauvais-JarvisF., VirkamakiA., MichaelM. D. (2000) A model to explore the interaction between muscle insulin resistance and beta-cell dysfunction in the development of type 2 diabetes. Diabetes, 49(12), 2126–2134.
40.
KimJ. K., MichaelM. D., PrevisS. F. (2000) Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J. Clin. Invest., 105(12), 1791–1797.
41.
WojtaszewskiJ. F., HigakiY., HirshmanM. F. (1999) Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J. Clin. Invest., 104(9), 1257–1264.
42.
MichaelM. D., KulkarniR. N., PosticC. (2000) Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol. Cell., 6(1), 87–97.
43.
CohenS. E., KokkotouE., BiddingerS. B. (2007) High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J. Biol. Chem., 282(32), 23672–23678.
44.
KulkarniR. N., BruningJ. C., WinnayJ. N., PosticC., MagnusonM. A., and KahnC. R. (1999) Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell., 96(3), 329–339.
45.
BluherM., MichaelM. D., PeroniO. D. (2002) Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell., 3(1), 25–38.
46.
BluherM., KahnB. B., and KahnC. R. (2003) Extended longevity in mice lacking the insulin receptor in adipose tissue. Science, 299(5606), 572–574.
47.
BluherM., PattiM. E., GestaS., KahnB. B., and KahnC. R. (2004) Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression. J. Biol. Chem., 279(30), 31891–31901.
48.
HavrankovaJ., RothJ., and BrownsteinM. (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature, 272(5656), 827–829.
49.
BruningJ. C., GautamD., BurksD. J. (2000) Role of brain insulin receptor in control of body weight and reproduction. Science, 289(5487), 2122–2125.
50.
LowellB. B., V.S.S., HamannA. (1993) Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature, 366(6457), 740–742.
51.
GuerraC., NavarroP., ValverdeA. M. (2001) Brown adipose tissue-specific insulin receptor knockout shows diabetic phenotype without insulin resistance. J. Clin. Invest., 108(8), 1205–1213.
52.
ZismanA., PeroniO. D., AbelE. D. (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med., 6(8), 924–928.
53.
KimY. B., PeroniO. D., AschenbachW. G. (2005) Muscle-specific deletion of the Glut4 glucose transporter alters multiple regulatory steps in glycogen metabolism. Mol. Cell. Biol., 25(21), 9713–9723.
54.
KimJ. K., ZismanA., FillmoreJ. J. (2001) Glucose toxicity and the development of diabetes in mice with muscle-specific inactivation of GLUT4. J. Clin. Invest., 108(1), 153–160.
55.
CarvalhoE., KotaniK., PeroniO. D., and KahnB. B. (2005) Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab., 289(4), E551–61.
56.
AbelE. D., PeroniO., KimJ.K. (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature, 409(6821), 729–733.
57.
KotaniK., PeroniO. D., MinokoshiY., BossO., and KahnB. B. (2004) GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J. Clin. Invest., 114(11), 1666–1675.
58.
Wallberg-HenrikssonH., and ZierathJ. R. (2001) GLUT4, a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Mol. Membr. Biol., 18(3), 205–211.
59.
RenJ. M., MarshallB. A., MuecklerM. M., McCalebM., AmatrudaJ. M., and ShulmanG. I. (1995) Overexpression of Glut4 protein in muscle increases basal and insulin-stimulated whole body glucose disposal in conscious mice. J. Clin. Invest., 95(1), 429–432.
60.
TozzoE., GnudiL., and KahnB. B. (1997) Amelioration of insulin resistance in streptozotocin diabetic mice by transgenic overexpression of GLUT4 driven by an adipose-specific promoter. Endocrinology, 138(4), 1604–1611.
61.
LeturqueA., LoizeauM., VaulontS., SalminenM., and GirardJ. (1996) Improvement of insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes, 45(1), 23–27.
62.
TiikkainenM., HakkinenA. M., KorsheninnikovaE., NymanT., MakimattilaS., and Yki-JarvinenH. (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53(8), 2169–2176.
63.
KitamuraT., KahnC. R., and AcciliD., (2003) Insulin receptor knockout mice. Annu. Rev. Physiol., 65, 313–332.
